초록 ▼

A microelectronic device package and method for manufacture. In one embodiment, the device package can include a microelectronic substrate having first and second device features, a conductive link that includes a conductive material extending between the first and second device features, and an ext

A microelectronic device package and method for manufacture. In one embodiment, the device package can include a microelectronic substrate having first and second device features, a conductive link that includes a conductive material extending between the first and second device features, and an external cover attached to the substrate and at least partially enclosing the first and second device features and the conductive link. The external cover can have a composition substantially identical to the composition of the conductive links and the external cover can be formed simultaneously with formation of the conductive link to reduce the number of process steps required to form the microelectronic device package. A sacrificial material can temporarily support the conductive link during manufacture and can subsequently be removed to suspend at least a portion of the conductive link between two points.

대표청구항 ▼

A microelectronic device package and method for manufacture. In one embodiment, the device package can include a microelectronic substrate having first and second device features, a conductive link that includes a conductive material extending between the first and second device features, and an ext

A microelectronic device package and method for manufacture. In one embodiment, the device package can include a microelectronic substrate having first and second device features, a conductive link that includes a conductive material extending between the first and second device features, and an external cover attached to the substrate and at least partially enclosing the first and second device features and the conductive link. The external cover can have a composition substantially identical to the composition of the conductive links and the external cover can be formed simultaneously with formation of the conductive link to reduce the number of process steps required to form the microelectronic device package. A sacrificial material can temporarily support the conductive link during manufacture and can subsequently be removed to suspend at least a portion of the conductive link between two points. stopper. 12. The product of claim 9, wherein the outer seal comprises a lid which is manually removable, to provide access to the stopper. 13. The product of claim 12, wherein the outer seal comprises an outer rim and a polypropylene lid, wherein the aluminum rim surrounds the lateral edge of the stopper and the polypropylene lid entirely covers the upper surface of the stopper. 14. A solution prepared by dissolving the product of claim 1 in an aqueous vehicle. 15. A method of producing a stable, sterile pharmaceutical product consisting essentially of lyophilized ifosfarnide, the method comprising: freezing a sterile solution consisting essentially of ifosfamide and an aqueous solvent to a temperature of from about -10° C. to about -70° C., to produce a frozen mixture; subjecting the frozen mixture to a primary drying stage, which comprises applying a vacuum to reduce the pressure by an amount effective to remove aqueous solvent from the frozen mixture, and, while applying the vacuum, raising the temperature to a primary drying temperature, wherein the primary drying temperature is from about -40° C. to about 25° C., to produce a first intermediate; and subjecting the first intermediate to a secondary drying stage, which comprises applying a vacuum to reduce the pressure by an amount effective to remove aqueous solvent from the first intermediate, and, while applying the vacuum, raising the temperature to a secondary drying temperature, wherein the secondary drying temperature is from about 0° C. to about 40° C., to produce the pharmaceutical product. 16. The method of claim 15, wherein the primary drying stage is carried out at a pressure of about 1000 mTorr or less. 17. The method of claim 16, wherein the primary drying stage is carried out at a pressure of about 200 mTorr or less. 18. The method of claim 15, wherein the sterile solution is frozen to a temperature of from about -30° C. to about -70° C. 19. The method of claim 18, wherein the sterile solution is frozen to a temperature of from about -40° C. to about -60° C. 20. The method of claim 15, wherein the primary drying temperature is from about -20° C. to about 10° C. 21. The method of claim 20, wherein the primary drying temperature is from about -15° C. to about -5° C. 22. The method of claim 15, wherein the temperature in the primary drying stage is raised at a rate of about 5° C. per minute or less. 23. The method of claim 22, wherein the temperature in the primary drying stage is raised at a rate of from about 0.1-3° C. per minute. 24. The method of claim 15, wherein the primary drying temperature in the primary drying stage is maintained until substantially all of the aqueous solvent is removed. 25. The method of claim 15, wherein the primary drying temperature in the primary drying stage is maintained until the temperature of the frozen mixture is about equal to the primary drying temperature. 26. The method of claim 15, wherein the secondary drying stage is carried out at a pressure of about 1000 mTorr or less. 27. The method of claim 26, wherein the secondary drying stage is carried out at a pressure of about 200 mTorr or less. 28. The method of claim 15, wherein the secondary drying temperature is from about 10° C. to about 40° C. 29. The method of claim 28, wherein the secondary drying temperature is from about 20° C. to about 30° C. 30. The method of claim 15, wherein the temperature in the secondary drying stage is raised at a rate of about 5° C. per minute or less. 31. The method of claim 30, wherein the temperature in the secondary drying stage is raised at a rate of from about 0.1-3° C. per minute. 32. The method of claim 15, wherein the secondary drying temperature in the secondary drying stage is held until the moisture content is about 0.5 wt % or less relative to the ifosfamide. 33. A method of administering ifosfamide to a patient in need thereof, the method comprising: dissolving the pharmaceutical product of cla im 1 in a pharmaceutically acceptable solvent to produce a pharmaceutically acceptable solution; and administering the solution to the patient. 34. A method of producing a stable, sterile pharmaceutical product consisting essentially of lyophilized ifosfamide, the method comprising: filling one or more containers, each container defining an opening, with a sterile solution consisting essentially of a therapeutically effective amount of ifosfamide and an aqueous solvent; freezing the sterile solution in the one or more containers to a temperature of from about -30° C. to about -70° C., to produce a frozen mixture; subjecting the frozen mixture to a primary drying stage, which comprises applying a vacuum to reduce the pressure by an amount effective to remove aqueous solvent from the frozen mixture, and, while applying the vacuum, raising the temperature to a primary drying temperature, wherein the primary drying temperature is from about -40° C. to about 25° C., to produce a first intermediate; subjecting the first intermediate to a secondary drying stage, which comprises applying a vacuum to reduce the pressure by an amount effective to remove aqueous solvent from the first intermediate, and, while applying the vacuum, raising the temperature to a secondary drying temperature, wherein the secondary drying temperature is from about 0° C. to about 40° C., to produce a solid consisting essentially of ifosfamide in the one or more containers; and sealing the opening of the one or more containers, to produce the pharmaceutical product. 35. The method of claim 34, wherein the one or more containers comprises one or more sterile glass vials and the sealing step comprises aseptically sealing the opening of the one or more glass vials with a stopper. 36. The method of claim 35, wherein the sterile solution has an ifosfamide concentration of about 130 mg/mL or less. 37. The method of claim 36, wherein the sterile solution has an ifosfamide concentration of about 100 mg/mL or less. 38. A pharmaceutical dosage form comprising a sealed container and a pharmaceutical product consisting essentially of a therapeutically effective amount of lyophilized ifosfamide contained within the container. 39. The pharmaceutical dosage form of claim 38, wherein the amount of lyophilized ifosfamide contained within the container is about 1.0 g or about 3.0 g.